+关注
Jingkai
暂无个人介绍
IP属地：未知
13
关注
5
粉丝
0
主题
0
勋章
主贴
热门
Jingkai
2021-12-04
Good
DocuSign stock craters to worst day on record after 'one of the biggest SaaS whiffs in recent memory'
Jingkai
2021-11-20
Nice
抱歉，原内容已删除
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3564023243270794,"uuid":"3564023243270794","gmtCreate":1600944978963,"gmtModify":1614680218021,"name":"Jingkai","pinyin":"jingkai","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/17fa55006583f12e0614ba5d4af99b77","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":5,"headSize":13,"tweetSize":14,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.06.24","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"60.41%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":608933006,"gmtCreate":1638591996429,"gmtModify":1638591996563,"author":{"id":"3564023243270794","authorId":"3564023243270794","name":"Jingkai","avatar":"https://static.tigerbbs.com/17fa55006583f12e0614ba5d4af99b77","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/608933006","repostId":"2188578706","repostType":4,"repost":{"id":"2188578706","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1638577500,"share":"https://www.laohu8.com/m/news/2188578706?lang=&edition=full","pubTime":"2021-12-04 08:25","market":"us","language":"en","title":"DocuSign stock craters to worst day on record after 'one of the biggest SaaS whiffs in recent memory'","url":"https://stock-news.laohu8.com/highlight/detail?id=2188578706","media":"Dow Jones","summary":"Electronic-signature company drops more than 40%, shedding nearly $20 billion of market cap as pande","content":"<p>Electronic-signature company drops more than 40%, shedding nearly $20 billion of market cap as pandemic boom in e-signature sales slows down</p>\n<p>DocuSign Inc. emerged as a hot pandemic stock play last year as it benefited from the need for digital contract tools, but the company lost more than 40% of its valuation Friday after suggesting the pandemic-induced demand boom is waning.</p>\n<p>Shares of DocuSign <a href=\"https://laohu8.com/S/DOCU\">$(DOCU)$</a> fell 42.2% Friday, by far their steepest single-day percentage decline on record, wiping away roughly $19.4 billion worth of market capitalization. DocuSign issued earnings Thursday evening with a disappointing billings outlook, and Chief Executive Dan Springer called out a \"return to more normalized buying patterns\" following a stretch of \"accelerated growth.\"</p>\n<p>The stock nearly tripled in 2020, pushing its market cap higher than $40 billion, but is now down 39.2% this year. In comparison, the S&P 500 index has rallied 21% this year after climbing 16% last year.</p>\n<p>The company's report served as \"a good reminder that even outstanding companies take their proverbial eye off the sales ball,\" Needham analyst Scott Berg wrote in a note downgrading DocuSign's stock to hold from buy. While DocuSign announced that it would be changing some elements of its sales organization, Berg said he has found that \"fixing these sales issues often requires several quarters.\"</p>\n<p>Citi Research analyst Tyler Radke wrote that DocuSign delivered \"one of the biggest SaaS [software-as-a-service] whiffs in recent memory with total billings growth of 28% significantly below [the] 34% guide\" during the fiscal third quarter. DocuSign's billings outlook for the fiscal fourth quarter was 22% at the midpoint, which came in significantly below the 32% consensus figure Radke cited in his note to clients.</p>\n<p>\"With a largely resilient performance vs [work-from-home] peers over the last two quarters, we are surprised that DOCU is seeing significant customer behavior/execution issues cropping up now, and in this magnitude,\" he continued.</p>\n<p>Radke called the report a \"thesis shifter,\" though he kept his buy rating on the stock, arguing that DocuSign has a \"first-mover advantage\" in its domain and that there are \"few signs\" that people are shifting back to manual agreements. He cut his target price to $231 from $389.</p>\n<p>Evercore ISI analyst Kirk Materne wrote that while DocuSign faced difficult comparisons in its most recent quarter, the company \"simply misread the market in terms of demand and that led to a faster than expected deceleration in billings growth.\"</p>\n<p>But the stock's sharp move downward indicates that \"the damage is essentially done as it relates to the quarter,\" he wrote. Further, after speaking with DocuSign's management team, Materne believes that DocuSign's fiscal fourth-quarter billing outlook \"assumes no improvement in demand [generation] vs. 3Q, which could prove conservative.\"</p>\n<p>While he called the stock's selloff \"a bit overdone,\" Materne admitted that \"the reality is this stock just went from a story where investors were thinking about durable growth being in the 30%'s to being in the 20%'s and that's going to create a pretty material de-rate.\"</p>\n<p>He cut his price target to $200 from $320, writing that \"until DOCU can show that it can generate, not just fulfill, demand on a regular basis, the multiple is capped.\" Materne kept an outperform rating on the stock, citing the long-term potential of e-signature technology especially in markets like government where DocuSign is \"very early\" in its penetration.</p>\n<p>DocuSign shares are off roughly 52% from their September closing high of $310.05.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DocuSign stock craters to worst day on record after 'one of the biggest SaaS whiffs in recent memory'</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDocuSign stock craters to worst day on record after 'one of the biggest SaaS whiffs in recent memory'\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-12-04 08:25</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Electronic-signature company drops more than 40%, shedding nearly $20 billion of market cap as pandemic boom in e-signature sales slows down</p>\n<p>DocuSign Inc. emerged as a hot pandemic stock play last year as it benefited from the need for digital contract tools, but the company lost more than 40% of its valuation Friday after suggesting the pandemic-induced demand boom is waning.</p>\n<p>Shares of DocuSign <a href=\"https://laohu8.com/S/DOCU\">$(DOCU)$</a> fell 42.2% Friday, by far their steepest single-day percentage decline on record, wiping away roughly $19.4 billion worth of market capitalization. DocuSign issued earnings Thursday evening with a disappointing billings outlook, and Chief Executive Dan Springer called out a \"return to more normalized buying patterns\" following a stretch of \"accelerated growth.\"</p>\n<p>The stock nearly tripled in 2020, pushing its market cap higher than $40 billion, but is now down 39.2% this year. In comparison, the S&P 500 index has rallied 21% this year after climbing 16% last year.</p>\n<p>The company's report served as \"a good reminder that even outstanding companies take their proverbial eye off the sales ball,\" Needham analyst Scott Berg wrote in a note downgrading DocuSign's stock to hold from buy. While DocuSign announced that it would be changing some elements of its sales organization, Berg said he has found that \"fixing these sales issues often requires several quarters.\"</p>\n<p>Citi Research analyst Tyler Radke wrote that DocuSign delivered \"one of the biggest SaaS [software-as-a-service] whiffs in recent memory with total billings growth of 28% significantly below [the] 34% guide\" during the fiscal third quarter. DocuSign's billings outlook for the fiscal fourth quarter was 22% at the midpoint, which came in significantly below the 32% consensus figure Radke cited in his note to clients.</p>\n<p>\"With a largely resilient performance vs [work-from-home] peers over the last two quarters, we are surprised that DOCU is seeing significant customer behavior/execution issues cropping up now, and in this magnitude,\" he continued.</p>\n<p>Radke called the report a \"thesis shifter,\" though he kept his buy rating on the stock, arguing that DocuSign has a \"first-mover advantage\" in its domain and that there are \"few signs\" that people are shifting back to manual agreements. He cut his target price to $231 from $389.</p>\n<p>Evercore ISI analyst Kirk Materne wrote that while DocuSign faced difficult comparisons in its most recent quarter, the company \"simply misread the market in terms of demand and that led to a faster than expected deceleration in billings growth.\"</p>\n<p>But the stock's sharp move downward indicates that \"the damage is essentially done as it relates to the quarter,\" he wrote. Further, after speaking with DocuSign's management team, Materne believes that DocuSign's fiscal fourth-quarter billing outlook \"assumes no improvement in demand [generation] vs. 3Q, which could prove conservative.\"</p>\n<p>While he called the stock's selloff \"a bit overdone,\" Materne admitted that \"the reality is this stock just went from a story where investors were thinking about durable growth being in the 30%'s to being in the 20%'s and that's going to create a pretty material de-rate.\"</p>\n<p>He cut his price target to $200 from $320, writing that \"until DOCU can show that it can generate, not just fulfill, demand on a regular basis, the multiple is capped.\" Materne kept an outperform rating on the stock, citing the long-term potential of e-signature technology especially in markets like government where DocuSign is \"very early\" in its penetration.</p>\n<p>DocuSign shares are off roughly 52% from their September closing high of $310.05.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4528":"SaaS概念","BK4023":"应用软件","DOCU":"Docusign"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2188578706","content_text":"Electronic-signature company drops more than 40%, shedding nearly $20 billion of market cap as pandemic boom in e-signature sales slows down\nDocuSign Inc. emerged as a hot pandemic stock play last year as it benefited from the need for digital contract tools, but the company lost more than 40% of its valuation Friday after suggesting the pandemic-induced demand boom is waning.\nShares of DocuSign $(DOCU)$ fell 42.2% Friday, by far their steepest single-day percentage decline on record, wiping away roughly $19.4 billion worth of market capitalization. DocuSign issued earnings Thursday evening with a disappointing billings outlook, and Chief Executive Dan Springer called out a \"return to more normalized buying patterns\" following a stretch of \"accelerated growth.\"\nThe stock nearly tripled in 2020, pushing its market cap higher than $40 billion, but is now down 39.2% this year. In comparison, the S&P 500 index has rallied 21% this year after climbing 16% last year.\nThe company's report served as \"a good reminder that even outstanding companies take their proverbial eye off the sales ball,\" Needham analyst Scott Berg wrote in a note downgrading DocuSign's stock to hold from buy. While DocuSign announced that it would be changing some elements of its sales organization, Berg said he has found that \"fixing these sales issues often requires several quarters.\"\nCiti Research analyst Tyler Radke wrote that DocuSign delivered \"one of the biggest SaaS [software-as-a-service] whiffs in recent memory with total billings growth of 28% significantly below [the] 34% guide\" during the fiscal third quarter. DocuSign's billings outlook for the fiscal fourth quarter was 22% at the midpoint, which came in significantly below the 32% consensus figure Radke cited in his note to clients.\n\"With a largely resilient performance vs [work-from-home] peers over the last two quarters, we are surprised that DOCU is seeing significant customer behavior/execution issues cropping up now, and in this magnitude,\" he continued.\nRadke called the report a \"thesis shifter,\" though he kept his buy rating on the stock, arguing that DocuSign has a \"first-mover advantage\" in its domain and that there are \"few signs\" that people are shifting back to manual agreements. He cut his target price to $231 from $389.\nEvercore ISI analyst Kirk Materne wrote that while DocuSign faced difficult comparisons in its most recent quarter, the company \"simply misread the market in terms of demand and that led to a faster than expected deceleration in billings growth.\"\nBut the stock's sharp move downward indicates that \"the damage is essentially done as it relates to the quarter,\" he wrote. Further, after speaking with DocuSign's management team, Materne believes that DocuSign's fiscal fourth-quarter billing outlook \"assumes no improvement in demand [generation] vs. 3Q, which could prove conservative.\"\nWhile he called the stock's selloff \"a bit overdone,\" Materne admitted that \"the reality is this stock just went from a story where investors were thinking about durable growth being in the 30%'s to being in the 20%'s and that's going to create a pretty material de-rate.\"\nHe cut his price target to $200 from $320, writing that \"until DOCU can show that it can generate, not just fulfill, demand on a regular basis, the multiple is capped.\" Materne kept an outperform rating on the stock, citing the long-term potential of e-signature technology especially in markets like government where DocuSign is \"very early\" in its penetration.\nDocuSign shares are off roughly 52% from their September closing high of $310.05.","news_type":1},"isVote":1,"tweetType":1,"viewCount":401,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876744739,"gmtCreate":1637369782085,"gmtModify":1637369782256,"author":{"id":"3564023243270794","authorId":"3564023243270794","name":"Jingkai","avatar":"https://static.tigerbbs.com/17fa55006583f12e0614ba5d4af99b77","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876744739","repostId":"1147615281","repostType":4,"isVote":1,"tweetType":1,"viewCount":523,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":876744739,"gmtCreate":1637369782085,"gmtModify":1637369782256,"author":{"id":"3564023243270794","authorId":"3564023243270794","name":"Jingkai","avatar":"https://static.tigerbbs.com/17fa55006583f12e0614ba5d4af99b77","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876744739","repostId":"1147615281","repostType":4,"repost":{"id":"1147615281","pubTimestamp":1637364985,"share":"https://www.laohu8.com/m/news/1147615281?lang=&edition=full","pubTime":"2021-11-20 07:36","market":"us","language":"en","title":"Pfizer Stock Leaps, Moderna Surges As FDA Approves Adult COVID Booster Shots","url":"https://stock-news.laohu8.com/highlight/detail?id=1147615281","media":"The Street","summary":"The Food & Drug Administration approved booster shots of both the Pfizer and Moderna Covid vaccines ","content":"<p>The Food & Drug Administration approved booster shots of both the Pfizer and Moderna Covid vaccines for all American adults Friday.</p>\n<p>$Pfizer Inc (<b>PFE</b>)$ shares jumped higher Friday, while $Moderna (<b>MRNA</b>)$ surged alongside it, after the U.S. Food & Drug Administration approved the use of their Covid booster shots in all American adults.</p>\n<p>The booster dose, the FDA said, can come six months after the completion of the two-shot series of both the Pfizer and Moderna vaccines following a review of Emergency Use Authorization approvals for both drugmakers. The FDA approved Pfizer's COVID vaccine, known as 'Comiranty', for booster shots inolder and at risk Americans in late September, one month after asimilar nod for Moderna's in immunocompromised individuals.</p>\n<p>A panel advising the Centers for Disease Control and Prevention will meet later Friday to assess the booster shot application as President Joe Biden continues to push for broader take-up of the vaccines heading into the winter months.</p>\n<p>That move followed a dire warning from outgoing German Chancellor Angela Merkel, who called the Covid situation \"dramatic\" as infections surge and fatalities rise.</p>\n<p>The lockdown, as well as fresh restrictions on movement and businesses in Germany, pushed the euro to a mid-July low of 1.1289 against the U.S. dollar and clipped bets on near-term energy demand in the world's biggest economic bloc.</p>\n<p>“As we near the two-year mark in our fight against COVID-19, we have reached another critical milestone with the expanded authorization of a booster dose of our COVID-19 vaccine in individuals 18 years and older,” said Pfizer CEO Albert Bourla. “With boosters, more adults will now have the opportunity to help preserve a high-level of protection against this disease. We are grateful to the FDA for their rigorous review, and the action taken today that we hope will help accelerate our path out of this pandemic.”</p>\n<p>Earlier this week, Pfizer agreed to sell 10 million doses of its developing Covid antiviral pill Paxlovid, which is currently being reviewed for Emergency Use Approval by the FDA, to the United States Department of Health and Human Services for around $5.3 billion.</p>\n<p>At $530 per tablet, the cost is around 25% cheaper than the $700 price agreed with Merck & Co. (<b>MRK</b>) last month to buy1.7 million doses its 'molnupiravir' treatmentof \"mild-to-moderate Covid in adults who are at risk for progressing to severe forms of disease, or hospitalization.</p>","source":"lsy1610613172068","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Stock Leaps, Moderna Surges As FDA Approves Adult COVID Booster Shots</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Stock Leaps, Moderna Surges As FDA Approves Adult COVID Booster Shots\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-20 07:36 GMT+8 <a href=https://www.thestreet.com/markets/pfizer-stock-leaps-moderna-surges-as-fda-approves-covid-boosters><strong>The Street</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Food & Drug Administration approved booster shots of both the Pfizer and Moderna Covid vaccines for all American adults Friday.\n$Pfizer Inc (PFE)$ shares jumped higher Friday, while $Moderna (MRNA...</p>\n\n<a href=\"https://www.thestreet.com/markets/pfizer-stock-leaps-moderna-surges-as-fda-approves-covid-boosters\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.thestreet.com/markets/pfizer-stock-leaps-moderna-surges-as-fda-approves-covid-boosters","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147615281","content_text":"The Food & Drug Administration approved booster shots of both the Pfizer and Moderna Covid vaccines for all American adults Friday.\n$Pfizer Inc (PFE)$ shares jumped higher Friday, while $Moderna (MRNA)$ surged alongside it, after the U.S. Food & Drug Administration approved the use of their Covid booster shots in all American adults.\nThe booster dose, the FDA said, can come six months after the completion of the two-shot series of both the Pfizer and Moderna vaccines following a review of Emergency Use Authorization approvals for both drugmakers. The FDA approved Pfizer's COVID vaccine, known as 'Comiranty', for booster shots inolder and at risk Americans in late September, one month after asimilar nod for Moderna's in immunocompromised individuals.\nA panel advising the Centers for Disease Control and Prevention will meet later Friday to assess the booster shot application as President Joe Biden continues to push for broader take-up of the vaccines heading into the winter months.\nThat move followed a dire warning from outgoing German Chancellor Angela Merkel, who called the Covid situation \"dramatic\" as infections surge and fatalities rise.\nThe lockdown, as well as fresh restrictions on movement and businesses in Germany, pushed the euro to a mid-July low of 1.1289 against the U.S. dollar and clipped bets on near-term energy demand in the world's biggest economic bloc.\n“As we near the two-year mark in our fight against COVID-19, we have reached another critical milestone with the expanded authorization of a booster dose of our COVID-19 vaccine in individuals 18 years and older,” said Pfizer CEO Albert Bourla. “With boosters, more adults will now have the opportunity to help preserve a high-level of protection against this disease. We are grateful to the FDA for their rigorous review, and the action taken today that we hope will help accelerate our path out of this pandemic.”\nEarlier this week, Pfizer agreed to sell 10 million doses of its developing Covid antiviral pill Paxlovid, which is currently being reviewed for Emergency Use Approval by the FDA, to the United States Department of Health and Human Services for around $5.3 billion.\nAt $530 per tablet, the cost is around 25% cheaper than the $700 price agreed with Merck & Co. (MRK) last month to buy1.7 million doses its 'molnupiravir' treatmentof \"mild-to-moderate Covid in adults who are at risk for progressing to severe forms of disease, or hospitalization.","news_type":1},"isVote":1,"tweetType":1,"viewCount":523,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":608933006,"gmtCreate":1638591996429,"gmtModify":1638591996563,"author":{"id":"3564023243270794","authorId":"3564023243270794","name":"Jingkai","avatar":"https://static.tigerbbs.com/17fa55006583f12e0614ba5d4af99b77","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/608933006","repostId":"2188578706","repostType":4,"repost":{"id":"2188578706","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1638577500,"share":"https://www.laohu8.com/m/news/2188578706?lang=&edition=full","pubTime":"2021-12-04 08:25","market":"us","language":"en","title":"DocuSign stock craters to worst day on record after 'one of the biggest SaaS whiffs in recent memory'","url":"https://stock-news.laohu8.com/highlight/detail?id=2188578706","media":"Dow Jones","summary":"Electronic-signature company drops more than 40%, shedding nearly $20 billion of market cap as pande","content":"<p>Electronic-signature company drops more than 40%, shedding nearly $20 billion of market cap as pandemic boom in e-signature sales slows down</p>\n<p>DocuSign Inc. emerged as a hot pandemic stock play last year as it benefited from the need for digital contract tools, but the company lost more than 40% of its valuation Friday after suggesting the pandemic-induced demand boom is waning.</p>\n<p>Shares of DocuSign <a href=\"https://laohu8.com/S/DOCU\">$(DOCU)$</a> fell 42.2% Friday, by far their steepest single-day percentage decline on record, wiping away roughly $19.4 billion worth of market capitalization. DocuSign issued earnings Thursday evening with a disappointing billings outlook, and Chief Executive Dan Springer called out a \"return to more normalized buying patterns\" following a stretch of \"accelerated growth.\"</p>\n<p>The stock nearly tripled in 2020, pushing its market cap higher than $40 billion, but is now down 39.2% this year. In comparison, the S&P 500 index has rallied 21% this year after climbing 16% last year.</p>\n<p>The company's report served as \"a good reminder that even outstanding companies take their proverbial eye off the sales ball,\" Needham analyst Scott Berg wrote in a note downgrading DocuSign's stock to hold from buy. While DocuSign announced that it would be changing some elements of its sales organization, Berg said he has found that \"fixing these sales issues often requires several quarters.\"</p>\n<p>Citi Research analyst Tyler Radke wrote that DocuSign delivered \"one of the biggest SaaS [software-as-a-service] whiffs in recent memory with total billings growth of 28% significantly below [the] 34% guide\" during the fiscal third quarter. DocuSign's billings outlook for the fiscal fourth quarter was 22% at the midpoint, which came in significantly below the 32% consensus figure Radke cited in his note to clients.</p>\n<p>\"With a largely resilient performance vs [work-from-home] peers over the last two quarters, we are surprised that DOCU is seeing significant customer behavior/execution issues cropping up now, and in this magnitude,\" he continued.</p>\n<p>Radke called the report a \"thesis shifter,\" though he kept his buy rating on the stock, arguing that DocuSign has a \"first-mover advantage\" in its domain and that there are \"few signs\" that people are shifting back to manual agreements. He cut his target price to $231 from $389.</p>\n<p>Evercore ISI analyst Kirk Materne wrote that while DocuSign faced difficult comparisons in its most recent quarter, the company \"simply misread the market in terms of demand and that led to a faster than expected deceleration in billings growth.\"</p>\n<p>But the stock's sharp move downward indicates that \"the damage is essentially done as it relates to the quarter,\" he wrote. Further, after speaking with DocuSign's management team, Materne believes that DocuSign's fiscal fourth-quarter billing outlook \"assumes no improvement in demand [generation] vs. 3Q, which could prove conservative.\"</p>\n<p>While he called the stock's selloff \"a bit overdone,\" Materne admitted that \"the reality is this stock just went from a story where investors were thinking about durable growth being in the 30%'s to being in the 20%'s and that's going to create a pretty material de-rate.\"</p>\n<p>He cut his price target to $200 from $320, writing that \"until DOCU can show that it can generate, not just fulfill, demand on a regular basis, the multiple is capped.\" Materne kept an outperform rating on the stock, citing the long-term potential of e-signature technology especially in markets like government where DocuSign is \"very early\" in its penetration.</p>\n<p>DocuSign shares are off roughly 52% from their September closing high of $310.05.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DocuSign stock craters to worst day on record after 'one of the biggest SaaS whiffs in recent memory'</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDocuSign stock craters to worst day on record after 'one of the biggest SaaS whiffs in recent memory'\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-12-04 08:25</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Electronic-signature company drops more than 40%, shedding nearly $20 billion of market cap as pandemic boom in e-signature sales slows down</p>\n<p>DocuSign Inc. emerged as a hot pandemic stock play last year as it benefited from the need for digital contract tools, but the company lost more than 40% of its valuation Friday after suggesting the pandemic-induced demand boom is waning.</p>\n<p>Shares of DocuSign <a href=\"https://laohu8.com/S/DOCU\">$(DOCU)$</a> fell 42.2% Friday, by far their steepest single-day percentage decline on record, wiping away roughly $19.4 billion worth of market capitalization. DocuSign issued earnings Thursday evening with a disappointing billings outlook, and Chief Executive Dan Springer called out a \"return to more normalized buying patterns\" following a stretch of \"accelerated growth.\"</p>\n<p>The stock nearly tripled in 2020, pushing its market cap higher than $40 billion, but is now down 39.2% this year. In comparison, the S&P 500 index has rallied 21% this year after climbing 16% last year.</p>\n<p>The company's report served as \"a good reminder that even outstanding companies take their proverbial eye off the sales ball,\" Needham analyst Scott Berg wrote in a note downgrading DocuSign's stock to hold from buy. While DocuSign announced that it would be changing some elements of its sales organization, Berg said he has found that \"fixing these sales issues often requires several quarters.\"</p>\n<p>Citi Research analyst Tyler Radke wrote that DocuSign delivered \"one of the biggest SaaS [software-as-a-service] whiffs in recent memory with total billings growth of 28% significantly below [the] 34% guide\" during the fiscal third quarter. DocuSign's billings outlook for the fiscal fourth quarter was 22% at the midpoint, which came in significantly below the 32% consensus figure Radke cited in his note to clients.</p>\n<p>\"With a largely resilient performance vs [work-from-home] peers over the last two quarters, we are surprised that DOCU is seeing significant customer behavior/execution issues cropping up now, and in this magnitude,\" he continued.</p>\n<p>Radke called the report a \"thesis shifter,\" though he kept his buy rating on the stock, arguing that DocuSign has a \"first-mover advantage\" in its domain and that there are \"few signs\" that people are shifting back to manual agreements. He cut his target price to $231 from $389.</p>\n<p>Evercore ISI analyst Kirk Materne wrote that while DocuSign faced difficult comparisons in its most recent quarter, the company \"simply misread the market in terms of demand and that led to a faster than expected deceleration in billings growth.\"</p>\n<p>But the stock's sharp move downward indicates that \"the damage is essentially done as it relates to the quarter,\" he wrote. Further, after speaking with DocuSign's management team, Materne believes that DocuSign's fiscal fourth-quarter billing outlook \"assumes no improvement in demand [generation] vs. 3Q, which could prove conservative.\"</p>\n<p>While he called the stock's selloff \"a bit overdone,\" Materne admitted that \"the reality is this stock just went from a story where investors were thinking about durable growth being in the 30%'s to being in the 20%'s and that's going to create a pretty material de-rate.\"</p>\n<p>He cut his price target to $200 from $320, writing that \"until DOCU can show that it can generate, not just fulfill, demand on a regular basis, the multiple is capped.\" Materne kept an outperform rating on the stock, citing the long-term potential of e-signature technology especially in markets like government where DocuSign is \"very early\" in its penetration.</p>\n<p>DocuSign shares are off roughly 52% from their September closing high of $310.05.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4528":"SaaS概念","BK4023":"应用软件","DOCU":"Docusign"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2188578706","content_text":"Electronic-signature company drops more than 40%, shedding nearly $20 billion of market cap as pandemic boom in e-signature sales slows down\nDocuSign Inc. emerged as a hot pandemic stock play last year as it benefited from the need for digital contract tools, but the company lost more than 40% of its valuation Friday after suggesting the pandemic-induced demand boom is waning.\nShares of DocuSign $(DOCU)$ fell 42.2% Friday, by far their steepest single-day percentage decline on record, wiping away roughly $19.4 billion worth of market capitalization. DocuSign issued earnings Thursday evening with a disappointing billings outlook, and Chief Executive Dan Springer called out a \"return to more normalized buying patterns\" following a stretch of \"accelerated growth.\"\nThe stock nearly tripled in 2020, pushing its market cap higher than $40 billion, but is now down 39.2% this year. In comparison, the S&P 500 index has rallied 21% this year after climbing 16% last year.\nThe company's report served as \"a good reminder that even outstanding companies take their proverbial eye off the sales ball,\" Needham analyst Scott Berg wrote in a note downgrading DocuSign's stock to hold from buy. While DocuSign announced that it would be changing some elements of its sales organization, Berg said he has found that \"fixing these sales issues often requires several quarters.\"\nCiti Research analyst Tyler Radke wrote that DocuSign delivered \"one of the biggest SaaS [software-as-a-service] whiffs in recent memory with total billings growth of 28% significantly below [the] 34% guide\" during the fiscal third quarter. DocuSign's billings outlook for the fiscal fourth quarter was 22% at the midpoint, which came in significantly below the 32% consensus figure Radke cited in his note to clients.\n\"With a largely resilient performance vs [work-from-home] peers over the last two quarters, we are surprised that DOCU is seeing significant customer behavior/execution issues cropping up now, and in this magnitude,\" he continued.\nRadke called the report a \"thesis shifter,\" though he kept his buy rating on the stock, arguing that DocuSign has a \"first-mover advantage\" in its domain and that there are \"few signs\" that people are shifting back to manual agreements. He cut his target price to $231 from $389.\nEvercore ISI analyst Kirk Materne wrote that while DocuSign faced difficult comparisons in its most recent quarter, the company \"simply misread the market in terms of demand and that led to a faster than expected deceleration in billings growth.\"\nBut the stock's sharp move downward indicates that \"the damage is essentially done as it relates to the quarter,\" he wrote. Further, after speaking with DocuSign's management team, Materne believes that DocuSign's fiscal fourth-quarter billing outlook \"assumes no improvement in demand [generation] vs. 3Q, which could prove conservative.\"\nWhile he called the stock's selloff \"a bit overdone,\" Materne admitted that \"the reality is this stock just went from a story where investors were thinking about durable growth being in the 30%'s to being in the 20%'s and that's going to create a pretty material de-rate.\"\nHe cut his price target to $200 from $320, writing that \"until DOCU can show that it can generate, not just fulfill, demand on a regular basis, the multiple is capped.\" Materne kept an outperform rating on the stock, citing the long-term potential of e-signature technology especially in markets like government where DocuSign is \"very early\" in its penetration.\nDocuSign shares are off roughly 52% from their September closing high of $310.05.","news_type":1},"isVote":1,"tweetType":1,"viewCount":401,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}
